CLOVIS ONCOLOGY Forum: Community User: Maroni

Am Montag kommen dann nachbörslich die Zahlen...

klasse

super

Ek erreicht.... Juhu

Uiuiiii

einfach mal 2,3 Jahre liegen lassen

Clovis Oncology Inc. (NASDAQ:CLVS) will post its Q216 quarterly earnings results on Monday, August 8th. Analysts expect Clovis Oncology to post earnings of ($2.13) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.39) by $0.22. During the same quarter last year, the business earned ($1.86) earnings per share. The company’s revenue was up NaN% on a year-over-year basis. On average, analysts expect Clovis Oncology to post $-8.00 EPS for the current fiscal year and $-4.85 EPS for the next fiscal year. Shares of Clovis Oncology Inc. (NASDAQ:CLVS) opened at 15.23 on Thursday. The firm’s market capitalization is $584.60 million. The firm has a 50-day moving average of $14.09 and a 200 day moving average of $16.52. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $116.75. A number of equities research analysts have recently commented on CLVS shares. Mizuho reduced their price objective on shares of Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a research note on Monday, April 11th. Piper Jaffray Cos. reissued a “neutral” rating and set a $18.00 target price on shares of Clovis Oncology in a research note on Tuesday, April 12th. Zacks Investment Research lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Stifel Nicolaus reissued a “buy” rating and set a $30.00 target price on shares of Clovis Oncology in a research note on Tuesday, April 12th. Finally, JPMorgan Chase & Co. lowered shares of Clovis Oncology from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $42.00 to $15.00 in a research note on Wednesday, April 13th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $29.25. Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

sieht auf jeden FALL so aus

Chart. ..Ausbruch oder wie soll ich das verstehen?

https://t.co/NqjTkmASkQ

mal sehen wo die Richtung zum 8.8 hingeht...

Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.

KOLs discuss #PARP inhibitor #rucaparib after $CLVS rejigs #LOH cutoff for #non-BRCA ovarian cancer patients

Nein machst du nicht. .hab kurz überflogen aber zZ gaaaanz gaaaanz wenig Zeit gehabt.Ab nächste WOCHE wirds ruhiger!!!Grüsse

Sieht so aus :) Und Infos verbreiten für investierte bzw interessierte Aktionäre

Vanhalen, redest du mit dir selbst?